Bristol Myers Squibb has been a strong performer in the six months, rising over 23% in that time. Investors desiring to ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 11,821 calls trading, 2x expected, and implied vol increasing almost 2 points to 27.82%. May-25 67.5 calls and Mar-25 60 calls are the ...

Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...